



## **BIOCRYST INVITES YOU TO JOIN ITS THIRD QUARTER 2000 CONFERENCE CALL**

Birmingham, Alabama – October 20, 2000 – BioCryst Pharmaceuticals, Inc. (Nasdaq; BCRX) invites you to participate in a quarterly conference call to discuss third quarter 2000 financial results on Wednesday October 25, 2000. Charles E. Bugg, Ph. D., Chairman & Chief Executive Officer, will host the call at 10:00 am Eastern Time.

To participate in this conference call please dial 1-800-289-0730. The call is expected to last no more than one hour and will include prepared remarks by senior BioCryst management with a subsequent question and answer period.

If you are unable to participate during the live conference call, a telephone replay will be available from 1pm Eastern Time October 25 through midnight Wednesday, November 1. To access the rebroadcast in the U.S., call 1-888-203-1112 and enter PASSCODE # 437678. International parties should dial 1-719-457-0820 and enter PASSCODE # 437678.

In addition, the call will be archived on BioCryst's Web site at [www.biocryst.com](http://www.biocryst.com).

Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of pharmaceuticals for the treatment of infectious, inflammatory and cardiovascular diseases and disorders. BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral influenza. The Company licensed this drug candidate to RWJPRI and Ortho-McNeil Pharmaceutical, Inc., both Johnson & Johnson (NYSE: JNJ) companies. For additional information on BioCryst, visit the company's web site at [www.biocryst.com](http://www.biocryst.com).